Andersons pediatric cardiology 153
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.57 KB, 3 trang )
Cardiacdiseaseburdenandriskofmortalityin
hospitalizedmusculardystrophypatients.
PediatrCardiol.2016;37:1290–1296.
239.BushbyK,FinkelR,BirnkrantDJ,etal.
DiagnosisandmanagementofDuchenne
musculardystrophy,part2:Implementationof
multidisciplinarycare.LancetNeurol.
2010;9:177–189.
240.StarcJJ,MooreRA,RattanMS,etal.Elevated
myocardialextracellularvolumefractionin
Duchennemusculardystrophy.PediatrCardiol.
2017.
241.HorKN,TaylorMD,Al-KhalidiHR,etal.
Prevalenceanddistributionoflategadolinium
enhancementinalargepopulationofpatients
withDuchennemusculardystrophy:Effectof
ageandleftventricularsystolicfunction.J
CardiovascMagnReson.2013;15:107.
242.MavrogeniS,BratisK,PapavasiliouA,etal.
CMRdetectssubclinicalcardiomyopathyin
mother-carriersofDuchenneandBecker
musculardystrophy.JACCCardiovascImaging.
2013;6:526–528.
243.LangSM,ShughS,MazurW,etal.Myocardial
fibrosisandleftventriculardysfunctionin
Duchennemusculardystrophycarriersusing
cardiacmagneticresonanceimaging.Pediatr
Cardiol.2015;36:1495–1501.
244.AmericanAcademyofPediatricsSectionon
CardiologyandCardiacSurgery.Cardiovascular
healthsupervisionforindividualsaffectedby
DuchenneorBeckermusculardystrophy.
Pediatrics.2005;116:1569–1573.
245.YoungMJ.Mechanismsofmineralocorticoid
receptor-mediatedcardiacfibrosisandvascular
inflammation.CurrOpinNephrolHypertens.
2008;17:174–180.
246.RamanSV,HorKN,MazurW,etal.Eplerenone
forearlycardiomyopathyinDuchennemuscular
dystrophy:Arandomised,double-blind,placebocontrolledtrial.LancetNeurol.2015;14:153–
161.
247.RamanSV,HorKN,MazurW,etal.Eplerenone
forearlycardiomyopathyinDuchennemuscular
dystrophy:Resultsofatwo-yearopen-label
extensiontrial.OrphanetJRareDis.
2017;12:39.
248.HeierCR,DamskerJM,YuQ,etal.VBP15,a
novelanti-inflammatoryandmembranestabilizer,improvesmusculardystrophywithout
sideeffects.EMBOMolMed.2013;5:1569–
1585.
249.KornegayJN.Thegoldenretrievermodelof
Duchennemusculardystrophy.SkeletMuscle.
2017;7:9.
250.TinsleyJM,FaircloughRJ,StorerR,etal.Daily
treatmentwithSMTC1100,anovelsmall
moleculeutrophinupregulator,dramatically
reducesthedystrophicsymptomsinthemdx
mouse.PLoSONE.2011;6:e19189.
251.RicottiV,SpintyS,RoperH,etal.Safety,
tolerability,andpharmacokineticsofSMT
C1100,a2-arylbenzoxazoleutrophinmodulator,
followingsingle-andmultiple-dose
administrationtopediatricpatientswith
Duchennemusculardystrophy.PLoSONE.
2016;11:e0152840.
252.SwaggartKA,McNallyEM.Modifiersofheart
andmusclefunction:Wheregeneticsmeets
physiology.ExpPhysiol.2014;99:621–626.
253.VieiraNM,SpinazzolaJM,AlexanderMS,etal.
Repressionofphosphatidylinositoltransfer
proteinalphaamelioratesthepathologyof
Duchennemusculardystrophy.ProcNatlAcad
SciUSA.2017;114:6080–6085.
254.Aartsma-RusA,StraubV,HemmingsR,etal.
Developmentofexonskippingtherapiesfor
Duchennemusculardystrophy:Acriticalreview
andaperspectiveontheoutstandingissues.
NucleicAcidTher.2017.
255.CharronP,VillardE,SebillonP,etal.Danon's
